Abstract
There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Current Neuropharmacology
Title: Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): Hideaki Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Abstract: There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi Hideaki, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017335
DOI https://dx.doi.org/10.2174/157015911795017335 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Chelation Therapies: A Chemical and Biochemical Perspective
Current Medicinal Chemistry Chronic Alcohol Abuse and HIV Disease Progression: Studies with the Non-Human Primate Model
Current HIV Research Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Targeting COVID-19 in Parkinson’s Patients: Drugs Repurposed
Current Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Chronographic Theory of Development, Aging, and Origin of Cancer: Role of Chronomeres and Printomeres
Current Aging Science Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
Mini-Reviews in Medicinal Chemistry Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology 2-Amino/Azido/Hydrazino-5-alkoxy-5H-[1]benzopyrano[4,3-d]pyrimidines:Synthesis and Pharmacological Evaluation
Medicinal Chemistry Adenosine A<sub>2A</sub> Receptor Antagonists as Positron Emission Tomography (PET) Tracers
Current Medicinal Chemistry Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Current Molecular Medicine Meningococcal Disease and Future Drug Targets
CNS & Neurological Disorders - Drug Targets Two Nitrogen-containing Ligands as Inhibitors of Metal-Induced Amyloid β-Peptide Aggregation
CNS & Neurological Disorders - Drug Targets Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy
Current Topics in Medicinal Chemistry Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews